CC-93269

Overview

CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.

SparkCures ID 311
Developed By Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
Generic Name CC-93269
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple...
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple...
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Interim results from the first study of CC-93269 in patients with relapsed/refractory multiple myeloma

January 22, 2020

  • The overall response rate (ORR) in all patients was 43.3% with a stringent complete response/complete response (sCR/CR) of 16.7%
  • The likelihood of response was dose-dependent. ORR by CC-93269 dose:
    • Dose ≤ 3mg (n= 7): 0%
    • Dose 3 to 6 mg or fixed-dose 6 mg (n= 14): 7%
    • Dose 6 to 10 mg or fixed-dose 10 mg (n= 9): 88.9%
  • Among the nine patients treated with 10 mg of CC-93269, the ORR was 88.9% with a sCR/CR of 44.4%
  • The median time to response was 4.1 weeks (range; 4–13.1)
  • Among 13 responding patients, 11 responses are ongoing
  • Measurable residual disease (MRD) negativity was achieved by 12 of the 13 responding patients
Read More

Resources

There are no resources, links or videos to display for this treatment.